Grantham Mayo Van Otterloo & Co. LLC Has $4.87 Million Stake in Medtronic PLC $MDT

Grantham Mayo Van Otterloo & Co. LLC lowered its stake in Medtronic PLC (NYSE:MDT) by 24.4% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 51,116 shares of the medical technology company’s stock after selling 16,507 shares during the quarter. Grantham Mayo Van Otterloo & Co. LLC’s holdings in Medtronic were worth $4,868,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Artisan Partners Limited Partnership increased its position in Medtronic by 2.6% in the 3rd quarter. Artisan Partners Limited Partnership now owns 1,234,550 shares of the medical technology company’s stock valued at $117,579,000 after buying an additional 31,314 shares in the last quarter. AXQ Capital LP boosted its holdings in Medtronic by 25.6% in the second quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after acquiring an additional 2,013 shares in the last quarter. UMB Bank n.a. boosted its holdings in Medtronic by 65.8% in the third quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after acquiring an additional 54,898 shares in the last quarter. Applied Finance Capital Management LLC acquired a new stake in Medtronic in the third quarter valued at approximately $1,308,000. Finally, Willis Investment Counsel grew its stake in Medtronic by 5.0% in the third quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock valued at $38,274,000 after acquiring an additional 19,192 shares during the period. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Up 0.4%

Shares of NYSE:MDT opened at $91.26 on Tuesday. The business’s 50 day moving average is $98.59 and its 200 day moving average is $97.02. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The stock has a market cap of $117.17 billion, a price-to-earnings ratio of 25.42, a PEG ratio of 2.28 and a beta of 0.71. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last released its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to analyst estimates of $8.89 billion. During the same period in the prior year, the firm posted $1.38 EPS. Medtronic’s quarterly revenue was up 5.8% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, sell-side analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, April 17th. Stockholders of record on Friday, March 27th will be issued a $0.71 dividend. The ex-dividend date is Friday, March 27th. This represents a $2.84 annualized dividend and a dividend yield of 3.1%. Medtronic’s dividend payout ratio is currently 79.11%.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on MDT shares. Royal Bank Of Canada upped their target price on Medtronic from $111.00 to $118.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Piper Sandler reissued a “neutral” rating on shares of Medtronic in a research report on Monday, January 5th. CICC Research initiated coverage on shares of Medtronic in a research note on Friday, January 30th. They set an “outperform” rating for the company. Leerink Partners lowered their price objective on shares of Medtronic from $120.00 to $119.00 and set an “outperform” rating on the stock in a report on Wednesday, February 18th. Finally, Jefferies Financial Group reaffirmed a “hold” rating and issued a $110.00 price objective on shares of Medtronic in a research note on Wednesday, November 19th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and a consensus target price of $110.74.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the firm’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.26% of the stock is owned by insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).